Clinical Trials
Key studies with hepatitis C therapy successfully completed
Published in Medical Letter on the CDC and FDA, March 12th, 2006
In addition, the company announced that it has completed 3-month animal toxicology studies that will support clinical studies of VX-950 of up to 3 months duration.
Initiation of additional phase 2 clinical studies in the U.S. in patients with HCV is planned following required Food and Drug Administration (FDA) review of these latest nonclinical and clinical results, and FDA review of a proposed clinical study protocol. This information will be submitted to the FDA within the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Cryptosporidiosis Outbreaks
Cryptosporidiosis outbreak associated with swimming pool exposure in water park - Human Papillomavirus Vaccine
Cervical mucosal antibodies protect against human papillomavirus 16 - Public Health
Pneumococcal vaccine in children decreases pneumococcal disease in HIV+ adults - Sexual & Reproductive Health
STD male-to-female ratio provides clues to behavior changes in men who have sex with men - Virology
One step, real time RT-PCR assay to detect hepatitis E virus has been developed - Acute Ischemic Stroke
Biopharma company to start phase IIa study with neuroprotectant Enecadin in acute ischemic stroke - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
